- Home
- ARWR vs KNSA Comparison
ARWR vs KNSA Comparison
Compare ARWR & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARWR
- KNSA
- Stock Information
- Founded
- ARWR 2003
- KNSA 2015
- Country
- ARWR United States
- KNSA United Kingdom
- Employees
- ARWR N/A
- KNSA N/A
- Industry
- ARWR Biotechnology: Pharmaceutical Preparations
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- ARWR Health Care
- KNSA Health Care
- Exchange
- ARWR Nasdaq
- KNSA Nasdaq
- Market Cap
- ARWR 1.8B
- KNSA 2.0B
- IPO Year
- ARWR 1993
- KNSA 2018
- Fundamental
- Price
- ARWR $13.03
- KNSA $26.03
- Analyst Decision
- ARWR Buy
- KNSA Strong Buy
- Analyst Count
- ARWR 11
- KNSA 6
- Target Price
- ARWR $41.44
- KNSA $38.00
- AVG Volume (30 Days)
- ARWR 1.6M
- KNSA 677.6K
- Earning Date
- ARWR 05-12-2025
- KNSA 04-29-2025
- Dividend Yield
- ARWR N/A
- KNSA N/A
- EPS Growth
- ARWR N/A
- KNSA N/A
- EPS
- ARWR N/A
- KNSA N/A
- Revenue
- ARWR $2,500,000.00
- KNSA $481,166,000.00
- Revenue This Year
- ARWR $4,380.43
- KNSA $37.21
- Revenue Next Year
- ARWR $64.24
- KNSA $1.53
- P/E Ratio
- ARWR N/A
- KNSA N/A
- Revenue Growth
- ARWR N/A
- KNSA 59.45
- 52 Week Low
- ARWR $9.57
- KNSA $17.38
- 52 Week High
- ARWR $30.41
- KNSA $28.56
- Technical
- Relative Strength Index (RSI)
- ARWR 47.38
- KNSA 63.21
- Support Level
- ARWR $12.44
- KNSA $25.97
- Resistance Level
- ARWR $14.97
- KNSA $28.56
- Average True Range (ATR)
- ARWR 0.74
- KNSA 1.24
- MACD
- ARWR 0.11
- KNSA 0.36
- Stochastic Oscillator
- ARWR 37.01
- KNSA 71.70
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.